Skip to content
Search

Latest Stories

UK working with Pfizer, AstraZeneca to increase vaccine supplies, says Hancock

Britain’s rollout of Covid-19 vaccines is being limited by the supply of shots, and the government is working with both Pfizer and AstraZeneca to increase supplies, health minister Matt Hancock said on Thursday.

“The rate limiting step is the supply of vaccine, and we’re working with the companies, both Pfizer and of course AstraZeneca, to increase the supply,” Hancock told broadcasters.


“The manufacturers are doing a brilliant job, and they’re delivering to the schedule that’s agreed, but that schedule is the amount of vaccine that we have ... we expect to see that amount of vaccine being delivered going up.”

He spoke after the Covid-19 vaccine developed by AstraZeneca and Oxford University was rolled out in doctors surgeries from Thursday, part of an effort to vaccinate of the most vulnerable within six weeks.

More than 1.3 million people in the United Kingdom have received one shot of either AstraZeneca or Pfizer’s Covid-19 vaccine.

Hancock said the aim was for most care home residents to be offered a shot by the end of January, with 13 million people in the top four priority cohorts reached by mid-February.

The government must ramp up shots to around two million a week to hit its target. The top priority groups include care home residents, the elderly, the clinically vulnerable, and frontline health and social care workers.

Prime Minister Boris Johnson has said that if the vaccine rollout goes to plan, new lockdown measures introduced this week could start to be eased in February. Johnson will give a news conference later on Thursday.

AstraZeneca’s vaccine was first deployed in hospitals on Monday. It does not have the ultra-low temperature requirements that Pfizer’s does, making it easier to roll out.

Initial boxes of the Pfizer vaccine contained nearly 1,000 doses, but the NHS said that smaller boxes of Pfizer’s vaccine had also been approved for use that could be used in settings like care homes without wasting doses.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less